Abstract
Modified low density lipoprotein (LDL) is considered to be a risk factor for the development and progression of atherosclerosis (1-3). Glycated LDL and oxidized LDL are the only modified lipoproteins that exist naturally in the human body, but oxidized LDL does not exist in the circulation because of the presence of many antioxidizing agents (4). LDL cannot be oxidized until it has entered the arterial wall from the circulation. The only modified LDL that exists in the circulation is glycated LDL. It has been shown to be more easily oxidized than native LDL (5-7). These findings indicate that the glycation of LDL may be the initial step in the development of atherosclerosis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lyons, T. J. (1991) Oxidized low density lipoproteins-A role in the pathogenesis of atherosclerosis in diabetes? Diabet. Med. 8, 411ā419.
Makita, T., Tanaka, A., Nakajima, K., Nakano, T., and Numano, N. (1999) Importance of glycation in acceleration of low density lipoprotein (LDL) uptake into macrophages in patients with diabetes mellitus. Int. Angiol. 18, 149ā153.
Makita, T., Tanaka, A., and Numano, F.(1999) Effect of glycated low density lipoprotein on smooth muscle cell proliferation. Int. Angiol., in press.
Colaco, C. A. L. S. and Roser, B. J.(1994) Atherosclerosis and glycation. Bio As says 16, 145ā147.
Lyon, T. J. (1992) Lipoprotein glycation and its metabolic consequences. Diabetes 41, 67ā73.
Wolff, S. P. and Dean, R. T.(1987) Glucose autoxidation and protein modification;the potential role of autoxidative glycation in diabetes mellitus. Biochem. J. 245, 243ā250.
Mullarkey, C. J., Edelstein, D., and Brownlee, M. (1990) Free radical generation by early glycation products; a mechanism for accelerated atherogenesis in diabetes. Biochem. Biophys. Res. Commun. 173, 932ā939.
Gonen, B., Baenziger, J., Schonfeld, G., Jacobson, D., and Farrar, P. (1981) Nonenzymatic glycosylation of low density lipoproteins in vitro. Effects on cellinteractive properties. Diabetes 30, 875ā878.
Schleicher, E., Deufel, T., and Wieland, O. H. (1981) Non-enzymatic glycosylation of human serum lipoproteins. FEBS Lett. 129, 1ā4.
Lopes-Virella, M. F. R., Klein, R. L., Lyons, T. J., Stevenson, H. C., and Witzum, J. L. (1988) Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes 37, 550ā557.
Gould, B. J., Hall, M., and Cook, J. G. H. (1984) A sensitive method for the measurement of glycosylated plasma proteins using affinity chromatography. Ann. Clin. Biochem. 21, 16ā21.
Dhima, K., Ito, N., Abe, F., Hirota, M., Yano, M., Yamamoto, Y., Uchida, T., and Noguchi, K. (1988) High performance liquid chromatography assay of serum glycated albumin. Diabetology 31, 327ā631.
Tanaka, A., Yui, K., Tomie, N., Baba, T., Tamura, M., Makita, T., Numano, F., Nakatani, S., and Kato, Y. (1997) New assay for glycated lipoproteins by highperformance liquid chromatography. Ann. N.Y. Acad. Sci. 811, 385ā394.
Okazaki, M., Sasamoto, K., Muramatsu, T., and Hosaki, S. (1997) Analysis of plasma lipoproteins by gel permeation chromatography, in Handbook of Lipoprotein Testing. (Rifai, N., ed.), AACC press, Washington, DC, pp. 531ā548.
Numano, F., Tanaka, A., Makita, T., and Kishi, Y. (1997) Glycated lipoprotein and atherosclerosis. Ann. N.Y. Acad. Sci. 811, 100ā114.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2001 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Tanaka, A. (2001). 9 Assay for Serum Glycated Lipoproteins. In: Drew, A.F. (eds) Atherosclerosis. Methods in Molecular Medicineā¢, vol 52. Humana Press. https://doi.org/10.1385/1-59259-073-X:105
Download citation
DOI: https://doi.org/10.1385/1-59259-073-X:105
Publisher Name: Humana Press
Print ISBN: 978-0-89603-751-9
Online ISBN: 978-1-59259-073-5
eBook Packages: Springer Protocols